Myriad Genetics (MYGN) Releases Favorable Prolaris Results
Zacks Investment Research | Feb 17, 2020 07:46AM ET
Myriad Genetics (NASDAQ:MYGN) recently released positive study outcome on Prolaris. The primary finding is that Prolaris can accurately identify which patient with intermediate or high-risk prostate cancer can be treated with multi-modality therapy and who can safely avoid such a treatment.
Prolaris is a genetic test designed by Myriad Genetics, which is equipped to directly measure tumor cell growth. The test combined with both prostate-specific antigen and Gleason can assess the degree of aggressiveness of a patient’s individual prostate cancer.
The study results show major progress in the company’s Oncology business.
More on the Study
The investigators studied 718 men with intermediate or high-risk prostate cancer. In the study, patients with a Prolaris score of greater than 2.112 (who are considered above the high-risk threshold), which constituted nearly 44% of the men in the study, were found to have significantly benefited from multi-modality therapy, which led to mitigation in the risk of metastases. Patients below the high-risk threshold were found to have received no benefit from multi-modality therapy, implying that such patients may opt for additional treatment.
Market Prospects
Per Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.